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1,2,3-triazole linked with 4-thiazolidinones: a one-
pot sequential approach†
Yogesh Kumar,ab Akanksha Matta,a Prashant Kumar,a Virinder S. Parmar,ab Erik V. Van
der Eyckenb and Brajendra K. Singh*a
A novel copper(I) catalyzed, microwave-assisted one-pot, four-component sequential reaction between a
propargyloxybenzaldehyde, a substituted phenyl azide, a substituted aniline and thioglycolic acid has been
developed for the synthesis of 3-phenyl-2-[4-{(1-phenyl-1H-1,2,3-triazol-4-yl)methoxy}phenyl]
thiazolidin-4-ones.Introduction
Thiazolidinones and 1,2,3-triazoles represent important classes
of drugs in medicinal chemistry. They are among the most
extensively investigated compounds by biochemists and
medicinal chemists.1 Thiazolidinones in particular show inter-
esting anticancer,2 anti-HIV,3 antimalarial,4 tuberculostatic,5
antihistaminic,6 anticonvulsant,7 antibacterial8 and anti-
arrythmic9 activities. Similarly, various triazole derivatives
possess antifungal,10 anticancer,11 antituberculosis12 and anti-
microbial13 activities.
So called hybrid molecules have been shown to be highly
active and eﬀective in medicinal chemistry. Synergistic
eﬀects are obtained via hybridization of two diﬀerent
bioactive moieties with complementary pharmacophoric
functions, or with diﬀerent modes of action.14 The conr-
mation of this hypothesis has been well established
in previous studies of 4-thiazolidinones coupled
with other heterocyclic fragments,15 i.e. resulting in high
antitumor activity. As a result, we have planned the
synthesis of linked thiazolidinone–triazole hybrid mole-
cules. 4-Thiazolidinones have been conveniently synthe-
sized by a three-component condensation of a primary
amine, an aldehyde, and either a mercaptoacetic or mer-
captopropanoic acid.15 This cyclocondensation could
be accelerated with N,N0-dicyclohexylcarbodiimide (DCC),16
2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexa-
uorophosphate (HBTU),17 g-ferrite,18 ZnCl2,19 sodiumistry, University of Delhi, Delhi 110 007,
ted Chemistry (LOMAC), Department of
), Celestijnenlaan 200F, B-3001 Leuven,
tion (ESI) available. See DOI:sulfate,20 [bmim][PF6],21 and activated y ash.22 The use of
microwave irradiation23 and polymer supported systems24
has also been reported. However, the main bottleneck of
these protocols is mostly harsh reaction conditions, pro-
longed heating, and the need for simultaneous removal of
water to accelerate the cyclocondensation. On the other
hand, the synthesis of 1,2,3-triazoles has been reported by
various methods,25 like copper-catalyzed azide–alkyne
cycloaddition (CuAAC) reaction26 and microwave-assisted
one-pot reaction of an alkyl halide, sodium azide and an
alkyne.27 We have recently reported the formation of 1,2,3-
triazoles using D-glucose as a reducing agent for the copper
catalyst.28 Very recently, metal free synthesis of 1,2,3-tri-
azoles has been also developed.29
Microwave irradiation is an alternative heating technique
based on the transformation of electromagnetic energy into
heat. Oen this method increases the rate of chemical reac-
tions30 and results in higher yields.
In recent years, multicomponent reactions (MCRs)28b,31
have received increasing attention due to their simplicity,
eﬃciency, atom economy, shortened reaction times, and the
possibility for diversity-oriented synthesis. The combination
of MCRs with transition metal-catalysis gives access to
complex molecules in few steps as compared to traditional
multistep processes. We have investigated the application
of microwave irradiation for the synthesis of our hybrid
molecules.Results and discussion
In view of the useful applications of 4-thiazolidinones and 1,2,3-
triazoles, we have developed a new microwave-assisted Cu(I)-
catalyzed one-pot, two step sequential synthesis via reaction of
an propargyloxybenzaldehyde, an aryl azide, an aniline and thi-
oglycolic acid under microwave irradiation. This synthesis could
be achieved by three diﬀerent pathways A, B and C (Scheme 1).This journal is © The Royal Society of Chemistry 2015
Scheme 1 Synthesis of thiazolidinone linked triazole.
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azole ring formation takes place, followed by the thiazolidinone
ring (Path A) or vice versa, i.e. formation of the thiazolidinone
ring followed by the triazole ring (Path B). However, alterna-
tively, one-pot, two-step synthesis could be employed, where
initially 4-(prop-2-yn-1-yloxy)benzaldehyde and an aryl azide are
reacted followed by addition of the aniline and thioglycolic acid,
to form the desired hybrid molecule (Path C). Interesting to
mention here that the second step where aniline and thio-
glycolic acid react with triazolyated intermediate didn't proceed
under conventional heating. Moreover, attempt to succeed this
reaction in a single step, one-pot manner was not feasible even
under microwave irradiation in contrast to the sequential
addition of the reactants as shown in Path C (Scheme 1).
Our initial investigation was focused on the screening of
various solvents to achieve the best yield under microwave
irradiation (Table 1). The reaction was unsuccessful when
carried out in polar aprotic solvents like tetrahydrofuran
(THF), acetonitrile (MeCN), 1,4-dioxane and non polar
aprotic solvent like toluene, while the reaction went to
completion when carried out in polar protic solvents, like
ethanol (EtOH) and methanol (MeOH) resulting in the
formation of the desired product in 33% and 29% yield,
respectively (Table 1, entries 5 and 6). To our delight, when
the reaction was carried out in an aqueous mixture of toluene
or THF, decent amounts of compound 8a were obtained
(Table 1, entries 7 and 8). The reaction did not run to
completion when it was carried out in chloroform or dioxane
mixed with water (Table 1, entries 9 and 10). Among the
screened aqueous solvent, THF–H2O (2 : 1) appeared to be
the most eﬀective (Table 1, entry 8).This journal is © The Royal Society of Chemistry 2015To investigate the scopeand limitations, variousphenyl azides
5a–c and anilines 7a–i were evaluated employing the optimized
conditions. All the screenedazides andanilines reacted smoothly
with propargyloxybenzaldehyde (3) and thioglycolic acid (6) and
aﬀorded the expected desired products 8a–d0 (Table 2) in good
yields. Anilines bearing either an electron donating group or
electron withdrawing group were well tolerated.
Conclusions
In summary, we have developed a convenient route for the
synthesis of thaizolidinones linked triazoles through a Cu
(I)-catalyzed one-pot sequential approach. The products
could be isolated in good yields. Work is ongoing to inves-




All microwave assisted experiments were run in a closed vial
applying a dedicated CEM-Discover monomode microwave
apparatus operating at a frequency of 2.45 GHz with continuous
irradiation power from 0 to 300 W (CEM Corporation, P.O. Box
200, Matthews, NC 28106). Analytical TLCs were performed on
Merck silica gel 60F254 plates. All liquid column chromato-
graphic separations were performed on column chromatog-
raphy. IR spectra were recorded on a Perkin-Elmer 2000 FT-IR
spectrometer at Department of Chemistry, University of Delhi.
The 1H and 13C NMR spectra (in CDCl3) were recorded on a
JEOL ECX-400P NMR/Bruker Avance at 400 MHz/300 MHz andRSC Adv., 2015, 5, 1628–1639 | 1629
Table 1 Optimization of the solvent systema
Entry Solvent Temp. (C) Time (min) Ist step +2nd step Yieldb (%)
1 Toluene 110 20 + 35 c
2 THF 70 20 + 25 c
3 MeCN 100 20 + 30 c
4 1,4-Dioxane 100 5 + 10 c
5 EtOH 85 15 + 55 33
6 MeOH 80 5 + 40 29
7 Toluene–H2O, (2 : 1) 90 5 + 35 50
8 THF–H2O, (2 : 1) 70 15 + 40 75
9 CHCl3–H2O, (2 : 1) 50 10 + 30 c
10 Dioxane–H2O, (2 : 1) 100 10 + 30 c
11 MeCN–H2O, (2 : 1) 75 15 + 70 17
a The rst step involves the reaction of 4-(prop-2-yn-1-yloxy)benzaldehyde (3) (1.8 mmol), phenyl azide (5a) (2.2 mmol), CuSO4$5H2O (0.35 mmol)
and D-glucose (0.75 mmol) in diﬀerent solvents under microwave irradiation for the indicated time and temperature at 100 W maximum power,
followed by the addition of aniline (7a) (2.2 mmol) and thioglycolic acid (6) (2.2 mmol) in the second step. b Isolated yields, c ¼ no reaction.
RSC Advances Paper100 MHz/75 MHz, respectively at USIC, University of Delhi/
Katholiek University Leuven, TMS was used as internal stan-
dard. The NMR spectra were processed by JEOL Delta™ NMR
data processing soware, the chemical shi values are on a d
scale and coupling constants (J) are in ppm and Hz respectively.
Abbreviations used are: s (singlet), d (doublet), t (triplet), dd
(double doublet) and m (multiplet). The high-resolution
mass spectral data was obtained using a JEOL JMS-SX-102A
spectrometer at Institute for Chemistry and Biochemistry,
Free University Berlin, Germany. Melting points were
recorded on a Buchi M-560 melting point apparatus and are
uncorrected. All the chemicals and reagents like phenol,
aniline, thioglycolic acid and propargyl bromide were
purchased from commercial sources and used as received
unless otherwise indicated.General procedure for the synthesis32 of 4-(prop-2-yn-1-yloxy)
benzaldehyde or propargyloxybenzaldehyde (3)
A mixture of 4-hydroxy benzaldehyde (1 mmol) and propargyl
bromide (1.2 mmol) in DMF (2 mL) as solvent was stirred with1630 | RSC Adv., 2015, 5, 1628–1639K2CO3 at r.t. for 24 h. The progress of the reaction was moni-
tored on TLC [ethyl acetate–petroleum ether (1 : 4)]. Aer
completion of the reaction, the mixture was extracted with ethyl
acetate (3  50 mL). The combined ethyl acetate layers were
dried over Na2SO4, ltered and concentrated under reduced
pressure. The crude product was directly used in the next step
without any further purication.General procedure for the synthesis33 of azidobenzene and its
derivatives (5a–c)
A mixture of appropriate aniline 4a–c (1 mmol) in HCl (17%,
5 mL) was stirred at 0 C. Sodium nitrite (1.5 equiv., dis-
solved in 5 mL of water) was added dropwise and stirring
continued at 0 C. Aer 15 min, sodium azide (1.5 equiv.,
dissolved in 5 mL of water) was added dropwise at 0 C and
the mixture was stirred for 3–4 h. The progress of the reac-
tion was monitored by TLC [ethyl acetate–petroleum ether
(1 : 5)]. Aer completion of the reaction, the reaction mixture
was extracted with ethyl acetate (3  50 mL). The combined
ethyl acetate layers were dried over Na2SO4, ltered andThis journal is © The Royal Society of Chemistry 2015
Table 2 Scope and limitations of the protocol employing diﬀerent phenyl azides 5a–c and anilines 7a–ia
Entry Compd R1 R2 Time (min) (Ist step)b + IInd step Yieldc (%)
1 8a H H 40 75
2 8b H 4-COCH3 50 82
3 8c H 3-COCH3 45 76
4 8d H 4-CH3 40 75
5 8e H 3-CH3 40 84
6 8f H 4-OCH3 40 82
7 8g H 2-OCH3 40 76
8 8h H 4-Br 45 62
9 8i H 3-F 40 71
10 8j CH3 H 45 85
11 8k CH3 4-COCH3 50 69
12 8l CH3 3-COCH3 40 74
13 8m CH3 4-CH3 40 87
14 8n CH3 3-CH3 45 80
15 8o CH3 4-OCH3 40 9
16 8p CH3 2-OCH3 40 70
17 8q CH3 4-Br 40 68
18 8r CH3 3-F 40 76
19 8s OCH3 H 45 76
20 8t OCH3 4-COCH3 40 76
21 8u OCH3 3-COCH3 40 83
22 8v OCH3 4-CH3 45 79
23 8w OCH3 3-CH3 50 73
24 8x OCH3 4-OCH3 40 87
25 8y OCH3 2-OCH3 40 80
26 8z OCH3 4-Br 40 74
27 8a0 OCH3 3-F 40 75
28 8b0 OCH3 4-F 40 78
29 8c0 OCH3 4-Cl 50 85
30 8d0 OCH3 2-Cl 50 77
a The rst step involves the reaction of 4-(prop-2-yn-1-yloxy)benzaldehyde (3) (1.8 mmol), phenyl azide (5a–c) (2.2 mmol), CuSO4$5H2O (0.35 mmol)
and D-glucose (0.75 mmol) in THF–H2O solvent under microwave irradiation for an appropriate time and temperature at 100 W maximum power,
followed by the addition of aniline (7a–i) (2.2 mmol) and thioglycollic acid (6) (2.2 mmol). b 15 min. c Isolated yields.
Paper RSC Advancesconcentrated under reduced pressure. The crude product
was directly used in the next step without any further
purication.Synthesis of 3-phenyl-2-(4-((1-phenyl-1H-1,2,3-triazol-4-yl)
methoxy)phenyl)thiazolidin-4-one and its derivatives (8a–d0)
A mixture of the alkyne (1 mmol), the appropriate azide
(1.2 mmol), CuSO4$5H2O (0.2 equiv.) and D-glucose were taken
in THF–H2O (2 : 1) in microwave transparent glass vial equip-
ped with a small magnetic stirring bar, and the vial was tightly
sealed with a Teon crimp cap. The mixture was thenThis journal is © The Royal Society of Chemistry 2015irradiated for 15 min at 70 C and 100 W maximum power. The
reaction mixture was cooled to r.t. and aniline (1.2 mmol) and
thioglycolic acid (1.2 mmol) were added. The reaction mixture
was irradiated again for appropriate time (40–50 min) at 70 C
and 100 W maximum power. The progress of the reaction was
monitored by TLC [ethyl acetate–petroleum ether (1 : 2)]. Aer
completion of the reaction, the mixture was extracted with
ethyl acetate (3  50 mL). The combined ethyl acetate layers
were dried over Na2SO4, ltered and concentrated under
reduced pressure. The crude product was puried by
column chromatography over silica gel to yield the desired
products 8a–d0.RSC Adv., 2015, 5, 1628–1639 | 1631
RSC Advances Paper3-Phenyl-2-[4-{(1-phenyl-1H-1,2,3-triazol-4-yl)methoxy}
phenyl]thiazolidin-4-one (8a).
It was obtained as white solid having m.p. 169–171 C in 75%
yield. IR (KBr) nmax (cm
1) ¼ 2931 (C–H, Ar), 1689 (C]O), 1226
(C–O), 765 (C–S–C); 1HNMR (300MHz, CDCl3) d 8.00 (s, 1H,H-5),
7.72 (dd, J ¼ 1.5, 6.5 Hz, 2H, Ar), 7.53–7.45 (m, 3H, Ar), 7.29–7.23
(m, 4H, Ar), 7.17–7.12 (m, 3H, Ar), 6.92 (dd, J ¼ 2.1, 6.5 Hz, 2H,
Ar), 6.07 (s, 1H, H-700), 5.24 (s, 2H, –OCH2), 3.98 (dd, J ¼ 1.5, 16.1
Hz, 1H, H-900), 3.87 (d, J ¼ 16.0 Hz, 1H, H-900); 13C NMR (75 MHz,
CDCl3) d 170.918 (C]O), 158.51 (C-100), 144.56, 137.45, 136.90,
131.89, 129.80, 129.09, 128.95, 128.64, 127.12, 125.89, 120.95,
120.61, 115.01, 65.31 (C-700), 61.99 (–OCH2), 33.58 (C-900); HRMS




It was obtained as a white solid with a m.p. of 123–125 C in 82%
yield. IR (KBr) nmax (cm
1) ¼ 2923 (–C–H, Ar), 1679 (C]O), 1599
(C]O), 1267 (C–O), 758 (C–S–C); 1H NMR (300 MHz, CDCl3) d
8.02 (s, 1H, H-5), 7.86 (d, J ¼ 7.5 Hz, 2H, Ar), 7.72 (d, J ¼ 7.32 Hz,
2H, Ar), 7.54–7.42 (m, 3H, Ar), 7.34–7.22 (m, 4H, Ar), 7.31 (d, J ¼
8.05 Hz, 2H, Ar), 7.25–7.21 (m, 2H, Ar), 6.93 (d, J ¼ 8.02 Hz, 2H,
Ar), 6.19 (s, 1H, H-700), 5.27 (s, 2H, –OCH2), 3.96 (d, J ¼ 16.2 Hz,
1H, H-900), 3.86 (d, J ¼ 16.2 Hz, 1H, H-900), 2.52 (s, 3H, –COCH3);
13C NMR (100 MHz, CDCl3) d 197.00 (–COCH3), 171.03 (C-1000),
158.59 (C-100), 144.39, 141.70, 136.81, 134.80, 131.18, 129.78,
129.11, 128.98, 128.34, 124.63, 121.02, 120.56, 115.15, 64.67
(C-700), 61.90 (–OCH2), 33.59 (C-900), 26.49 (–COCH3); HRMS
calcd for C26H22N4O3SH: 471.5508; found [M + H]
+: 471.5514.
3-(3-Acetylphenyl)-2-[4-{(1-phenyl-1H-1,2,3-triazol-4-yl)
methoxy}phenyl] thiazolidin-4-one (8c).1632 | RSC Adv., 2015, 5, 1628–1639It was obtained as a brown semi solid in 76% yield. IR (KBr) nmax
(cm1) ¼ 2925 (C–H, Ar), 1685 (C]O), 1598 (C]O), 1240 (C–O),
758 (C–S–C); 1H NMR (300MHz, CDCl3) d 8.02 (s, 1H, H-5), 7.74–
7.70 (m, 4H, Ar), 7.55–7.44 (m, 5H, Ar) 7.38–7.36 (m, 2H, Ar),
6.92 (dd, J ¼ 2.2, 6.5 Hz, 2H, Ar), 6.14 (s, 1H, H-700), 5.22 (s, 2H,
–OCH2), 3.98 (dd, J¼ 1.7, 14.6 Hz, 1H, H-900), 3.88 (d, J¼ 15.6 Hz,
1H, H-900), 2.50 (s, 3H, –COCH3);
13C NMR (100 MHz, CDCl3) d
197.08 (–COCH3), 171.12 (C-1000), 158.59 (C-100), 144.38, 137.84,
137.76, 136.89, 131.16, 130.47, 129.77, 129.32, 128.98, 128.73,
126.89, 125.23, 121.02, 120.56, 115.06, 65.06 (C-700), 61.83
(–OCH2), 33.54 (C-900), 26.56 (–COCH3); HRMS calcd for




It was obtained as a yellowish solid with a m.p. of 166.0–168.0
C in 75% yield. IR (KBr) nmax (cm
1) ¼ 2924 (C–H, Ar), 1681
(C]O), 1239 (C–O), 757 (C–S–C); 1H NMR (400 MHz, CDCl3) d
8.01 (s, 1H, H-5), 7.70 (d, J ¼ 8.05 Hz, 2H, Ar), 7.49 (d, J ¼ 7.32
Hz, 2H, Ar) 7.45–7.41 (m, 1H, Ar), 7.24–7.21 (m, 2H, Ar), 7.04 (d, J
¼ 7.32 Hz, 2H, Ar), 6.97 (d, J ¼ 8.05 Hz, 2H, Ar), 6.90 (d, J ¼ 8.05
Hz, 2H, Ar), 6.00 (s, 1H, H-700), 5.22 (s, 2H, –OCH2), 3.95 (d, J¼
16.1 Hz, 1H, H-900), 3.85 (d, J ¼ 16.1 Hz, 1H, H-900), 2.22 (s, 3H,
–CH3);
13C NMR (100 MHz, CDCl3) d 170.12 (C-1000), 158.42
(C-100), 144.45, 137.07, 136.78, 134.62, 131.92, 129.70, 128.89,
128.64, 125.84, 120.99, 120.52, 114.89, 65.35 (C-700), 61.88
(–OCH2), 33.46 (C-900), 20.93 (–CH3); HRMS calcd for




It was obtained as a yellowish solid with a m.p. of 181–183 C in
84% yield. IR (KBr) nmax (cm
1) ¼ 2924 (C–H, Ar), 1681 (C]O),
1238 (C–O), 759 (C–S–C); 1H NMR (400 MHz, CDCl3) d 8.01 (s, 1H,
H-5), 7.70 (d, J ¼ 7.32 Hz, 2H, Ar), 7.52–7.49 (m, 2H, Ar), 7.45–7.41
(m, 1H, Ar), 7.24–7.21 (m, 2H, Ar), 7.13–7.09 (m, 1H, Ar), 6.95–6.85
(m, 5H, Ar), 6.02 (s, 1H, H-700), 5.23 (s, 2H, –OCH2), 3.95 (d, J¼ 1.46,
16.11 Hz, 1H, H-900), 3.84 (d, J ¼ 16.11 Hz, 1H, H-900), 2.23 (s, 3H,
–CH3);
13C NMR (100 MHz, CDCl3) d 170.96 (C-1000), 158.43 (C-100),
144.50, 139.00, 137.24, 136.82, 131.96, 129.75, 128.93, 128.81,
128.60, 128.05, 126.66, 122.93, 120.96, 120.56, 114.91, 65.36 (C-700),This journal is © The Royal Society of Chemistry 2015
Paper RSC Advances61.90 (–OCH2), 33.52 (C-900), 21.29 (–CH3); HRMS calcd for




It was obtained as a brown semi solid in 82% yield. IR (KBr) nmax
(cm1) ¼ 2926 (C–H, Ar), 1676 (C]O), 1215 (C–O), 758 (C–S–C);
1HNMR (300MHz, CDCl3) d 8.02 (s, 1H,H-5), 7.72 (dd, J¼ 2.0, 7.6
Hz, 2H, Ar), 7.55–7.44 (m, 3H, Ar), 7.26–7.22 (m, 2H, Ar), 7.00–6.91
(m, 4H, Ar), 6.79–6.76 (m, 2H, Ar), 5.96 (s, 1H, H-700), 5.24 (s, 2H,
–OCH2), 3.97 (dd, J¼ 1.7, 16.11 Hz, 1H, H-900), 3.86 (d, J¼ 16.0 Hz,
1H, H-900) 3.71 (s, 3H, –OCH3);
13C NMR (100 MHz, CDCl3) d
171.14 (C-1000), 158.52 (C-100), 144.51, 136.84, 131.91, 129.90,
129.77, 128.95, 128.83, 127.62, 120.97, 120.58, 114.91, 114.42,
65.67 (C-700), 61.89 (–OCH2), 55.28 (–OCH3), 33.40 (C-900); HRMS




It was obtained as a white solid with a m.p. of 168.0–170.0 C in
76% yield. IR (KBr) nmax (cm
1) ¼ 2926 (C–H, Ar), 1686 (C]O),
1236 (C–O), 761 (C–S–C); 1H NMR (300MHz, CDCl3) d 8.00 (s, 1H,
H-5), 7.69 (d, J¼ 8.79 Hz, 2H, Ar), 7.52–7.41 (m, 3H, Ar), 7.26–7.24
(m, 2H, Ar), 6.87–6.82 (m, 4H, Ar), 6.77–6.74 (m, 1H, Ar), 6.05 (s,
1H, H-700), 5.20 (s, 2H, –OCH2), 3.90–3.80 (m, 2H, H-900), 3.79 (s,
3H, –OCH3);
13C NMR (100 MHz, CDCl3) d 171.52 (C-1000), 158.45
(C-100), 154.74, 144.50, 136.78, 131.32, 130.29, 129.74, 129.49,
129.39, 128.94, 125.24, 120.94, 120.71, 120.54, 114.53, 111.81,
64.35 (C-700), 61.79 (–OCH2), 55.59 (–OCH3), 33.24 (C-900); HRMS
calcd for C25H22N4O3SH: 459.5401; found [M + H]
+: 459.5409.
3-(4-Bromophenyl)-2-[4-{(1-phenyl-1H-1,2,3-triazol-4-yl)
methoxy}phenyl] thiazolidin-4-one (8h).This journal is © The Royal Society of Chemistry 2015It was obtained as a yellow solid with a m.p. of 87.0–89.0 C in
62% yield. IR (KBr) nmax (cm
1) ¼ 2925 (C–H, Ar), 1685 (C]O),
1216 (C–O), 758 (C–S–C); 1H NMR (400 MHz, CDCl3) d 8.03 (s,
1H, H-5), 7.72 (d, J¼ 8.05 Hz, 2H, Ar), 7.53–7.43 (m, 3H, Ar), 7.38
(d, J ¼ 8.79 Hz, 2H, Ar), 7.22 (d, J ¼ 8.05 Hz, 2H, Ar), 7.02 (d, J ¼
8.05 Hz, 2H, Ar), 6.93 (d, J ¼ 8.05 Hz, 2H, Ar), 6.04 (s, 1H, H-700),
5.25 (s, 2H, –OCH2), 3.95 (d, J ¼ 16.11 Hz, 1H, H-900), 3.85 (d, J ¼
15.38 Hz, 1H, H-900); 13C NMR (100 MHz, CDCl3) d 170.90 (C-
1000), 158.62 (C-100), 144.49, 136.85, 136.45, 132.18, 131.32,
129.79, 128.99, 128.60, 127.23, 121.00, 120.59, 115.11, 65.05 (C-
700), 61.94 (–OCH2), 33.48 (C-900); HRMS calcd for C24H19BrN4-




It was obtained as a white solid with a m.p. of 156.0–158.0 C in
71% yield. IR (KBr) nmax (cm
1) ¼ 2926 (C–H, Ar), 1675 (C]O),
1243 (C–O), 760 (C–S–C); 1H NMR (400 MHz, CDCl3) d 8.01 (s,
1H, H-5), 7.72 (dd, J ¼ 1.09, 8.01 Hz, 2H, Ar), 7.54–7.51 (m, 2H,
Ar), 7.47–7.43 (m, 1H, Ar), 7.25–7.19 (m, 3H, Ar), 6.98–6.82 (m,
5H, Ar), 6.07 (s, 1H, H-700), 5.24 (s, 2H, –OCH2), 3.95 (dd, J ¼ 1.6,
16.1 Hz, 1H, H-900), 3.85 (d, J¼ 16.1 Hz, 1H, H-900); 13C NMR (100
MHz, CDCl3) d 170.94 (C-1000), 158.60 (C-100), 144.47, 131.44,
129.79, 128.96, 128.43, 120.93, 120.60, 115.12, 114.01, 113.84,
113.08, 112.85, 64.99 (C-700), 61.97 (–OCH2), 33.48 (C-900); HRMS




It was obtained as a dark brown solid with a m.p. of 152.0–154.0
C in 85% yield. IR (KBr) nmax (cm
1) ¼ 2925 (C–H, Ar), 1701
(C]O), 1228 (C–O), 826 (C–S–C); 1H NMR (400 MHz, CDCl3) d
8.05 (s, 1H, H-5), 7.72 (d, J ¼ 8.05 Hz, 2H, Ar), 7.54–7.43 (m, 4H,
Ar), 7.26–7.23 (m, 1H, Ar), 7.06 (d, J ¼ 7.32 Hz, 2H, Ar), 6.99 (d, J
¼ 8.05 Hz, 2H, Ar), 6.92 (d, J ¼ 8.05 Hz, 2H, Ar), 6.02 (s, 1H,
H-700), 5.24 (s, 2H, –OCH2), 3.97 (d, J ¼ 15.38 Hz, 1H, H-900), 3.87
(d, J ¼ 16.11 Hz, 1H, H-900), 2.24 (s, 2H, –CH3); 13C NMR (100
MHz, CDCl3) d 171.48 (C-1000), 158.93 (C-100), 144.97, 137.59,
137.29, 135.14, 132.44, 130.22, 129.41, 129.16, 126.35, 121.50,
121.03, 115.40, 65.87 (C-700), 62.40 (–OCH2), 33.97 (C-900), 21.45
(–CH3); HRMS calcd for C25H22N4O2SH: 443.5407; found [M +
H]+: 443.5401.RSC Adv., 2015, 5, 1628–1639 | 1633
RSC Advances Paper3-(4-Acetylphenyl)-2-[4-{(1-(p-tolyl)-1H-1,2,3-triazol-4-yl)
methoxy}phenyl] thiazolidin-4-one (8k).
It was obtained as a white solid with a m.p. of 137.0–139.0 C in
69% yield. IR (KBr) nmax (cm
1) ¼ 2917 (C–H, Ar), 1683 (C]O),
1227 (C–O), 750 (C–S–C); 1H NMR (400 MHz, CDCl3) d 7.97 (s,
1H, H-5), 7.86 (d, J ¼ 8.6 Hz, 2H, Ar), 7.58 (d, J ¼ 8.6 Hz, 2H, Ar),
7.33–7.29 (m, 4H, Ar), 7.23 (d, J ¼ 8.6 Hz, 1H, Ar), 7.21 (m, 1H,
Ar), 6.93 (d, J ¼ 8.00 Hz, 2H, Ar), 6.18 (s, 1H, H-7), 5.22 (s, 2H,
–OCH2), 3.95 (d, J ¼ 16.8 Hz, 1H, H-900), 3.87 (d, J ¼ 16.8 Hz, 1H,
H-900), 2.51 (s, 3H, –COCH3), 2.41 (s, 3H, –CH3);
13C NMR (100
MHz, CDCl3) d 197.05 (–COCH3), 170.97 (C-1000), 158.49 (C-100),
144.31, 141.67, 139.21, 134.85, 134.57, 131.14, 130.26, 129.13,
128.32, 124.62, 120.98, 120.47, 115.17, 64.91 (C-700), 61.69
(–OCH2), 33.60 (C-900), 26.53 (–COCH3), 21.08 (–CH3); HRMS




It was obtained as a dark brown semi solid in 74% yield. IR (KBr)
nmax (cm
1) ¼ 2923 (C–H, Ar), 1682 (C]O), 1240 (C–O), 757 (C–S–
C); 1H NMR (400 MHz, CDCl3) d 7.98 (s, 1H, H-5), 7.73–7.70 (m,
2H, Ar), 7.57 (d, J ¼ 8.72 Hz, 2H, Ar), 7.36–7.35 (m, 2H, Ar), 7.30–
7.26 (m, 4H, Ar), 6.91 (d, J ¼ 8.70 Hz, 2H, Ar), 6.13 (s, 1H, H-700),
5.20 (s, 2H, –OCH2), 3.97 (d, J ¼ 16.03 Hz, 1H, H-900), 3.88 (d, J ¼
16.03 Hz, 1H, H-900), 2.49 (s, 3H, –COCH3), 2.40 (s, 3H, –CH3);
13C
NMR (100 MHz, CDCl3) d 197.01 (–COCH3), 171.06 (C-1000), 158.55
(C-100), 144.19, 138.89, 137.76, 134.48, 131.03, 130.44, 130.21,
129.28, 128.69, 126.84, 125.21, 120.98, 120.43, 115.03, 65.02 (C-700),
61.84 (–OCH2), 33.52 (C-900), 26.53 (–COCH3), 21.04 (–CH3); HRMS
calcd for C27H24N4O3SH: 485.5774; found [M + H]
+: 485.5779.
3-(p-Tolyl)-2-[4-{(1-(p-tolyl)-1H-1,2,3-triazol-4-yl)methoxy}
phenyl]thiazolidin-4-one (8m).1634 | RSC Adv., 2015, 5, 1628–1639It was obtained as a white solid with a m.p. of 159.0–161.0 C in
87% yield. IR (KBr) nmax (cm
1) ¼ 2925 (C–H, Ar), 1690 (C]O),
1232 (C–O), 819 (C–S–C); 1H NMR (400 MHz, CDCl3) d 7.97 (s,
1H, H-5), 7.59 (d, J¼ 2.48, 6.4 Hz, 2H, Ar), 7.31 (d, J¼ 8.4 Hz, 2H,
Ar), 7.25–7.23 (m, 2H, Ar), 7.06 (d, J ¼ 8.4 Hz, 2H, Ar), 7.04–6.97
(m, 2H, Ar), 6.93 (dd, J ¼ 2.4, 6.8 Hz, 2H, Ar), 6.01 (s, 1H, H-700),
5.22 (s, 2H, –OCH2), 3.97 (dd, J¼ 1.6, 15.6 Hz, 1H, H-900), 3.86 (d,
J¼ 15.6 Hz, 1H, H-900), 2.42 (s, 3H, –CH3), 2.24 (s, 3H, –CH3); 13C
NMR (100 MHz, CDCl3) d 171.02 (C-1000), 158.47 (C-100), 144.30,
139.08, 137.12, 134.63, 134.53, 131.90, 130.22, 129.73, 128.66,
125.87, 120.94, 120.45, 114.90, 65.39 (C-700), 61.87 (–OCH2),
33.48 (C-900), 21.05 (–CH3), 20.96 (–CH3); HRMS calcd for




It was obtained as a white solid with a m.p. of 227.0–229.0 C in
80% yield. IR (KBr) nmax (cm
1) ¼ 2926 (C–H, Ar), 1676 (C]O),
1237 (C–O), 824 (C–S–C); NMR (300 MHz, CDCl3) d 7.97 (s, 1H,
H-5), 7.58 (dd, J ¼ 2.4, 8.4 Hz, 2H, Ar), 7.32–7.21 (m, 4H, Ar),
7.16–7.1028 (m, 1H, Ar), 7.97–6.86 (m, 5H, Ar), 6.04 (s, 1H, H-700),
5.22 (s, 2H, –OCH2), 3.97 (dd, J¼ 2.4, 21.2 Hz, 2H, H-900), 3.85 (d,
J¼ 15.3 Hz, 1H, H-900), 2.41 (s, 3H, –CH3), 2.21 (s, 3H, –CH3); 13C
NMR (100 MHz, CDCl3) d 171.50 (C-1000), 158.95 (C-100), 144.78,
139.57, 137.60, 135.12, 135.01, 132.38, 130.70, 130.22, 129.15,
126.35, 121.42, 120.94, 115.38, 65.88 (C-700), 62.36 (–OCH2),
33.96 (C-900), 21.53 (–CH3), 21.44 (–CH3); HRMS calcd for




It was obtained as a yellowish solid with a m.p. of 123.0–125.0
C in 69% yield. IR (KBr) nmax (cm
1) ¼ 2923 (C–H, Ar), 1678
(C]O), 1246 (C–O), 757 (C–S–C); 1H NMR (400 MHz, CDCl3) d
7.98 (s, 1H, H-5), 7.60 (d, J ¼ 8.4 Hz, 2H, Ar), 7.32 (d, J ¼ 8.0 Hz,
2H, Ar), 7.26–7.23 (m, 2H, Ar), 7.00 (dd, J ¼ 2.0, 6.8 Hz, 2H, Ar),
6.94 (d, J¼ 8.4 Hz, 2H, Ar), 6.79 (dd, J¼ 2.7, 7.3 Hz, 2H, Ar), 5.96
(s, 1H, H-700), 5.24 (s, 2H, –OCH2), 3.98 (dd, J ¼ 1.6, 15.6 Hz, 1H,
H-900), 3.87 (d, J ¼ 16.0 Hz, 1H, H-900), 3.73 (s, 3H, –OCH3), 2.43
(s, 3H, –CH3);
13C NMR (100 MHz, CDCl3) d 171.04 (C-1000),
158.53 (C-100), 144.30, 139.12, 134.50, 131.90, 130.26, 129.93,
128.82, 127.62, 120.98, 120.48, 114.90, 114.41, 65.62 (C-700),This journal is © The Royal Society of Chemistry 2015
Paper RSC Advances61.90 (–OCH2), 55.28 (–OCH3), 33.40 (C-900), 21.07 (–CH3); HRMS




It was obtained as a white solid with a m.p. of 237.0–239.0 C in
70% yield. IR (KBr) nmax (cm
1) ¼ 2922 (C–H, Ar), 1672 (C]O),
1271 (C–O), 757 (C–S–C); 1H NMR (300 MHz, CDCl3) d 7.95 (s,
1H, H-5), 7.59 (d, J¼ 8.8 Hz, 2H, Ar), 7.32–7.14 (m, 5H, Ar), 6.90–
6.75–7.20 (m, 5H, Ar), 6.06 (s, 1H, H-700), 5.21 (s, 2H, –OCH2),
3.90 (s, 2H, H-900), 3.82 (s, 3H, –OCH3), 2.42 (s, 3H, –CH3);
13C
NMR (100 MHz, CDCl3) d 171.10 (C-1000), 159.99 (C-1200), 158.45
(C-100), 141.18, 137.18, 134.58, 131.92, 129.76, 128.69, 125.90,
122.25, 121.22, 120.03, 114.91, 114.78, 65.44 (C-700), 61.82
(–OCH2), 55.61 (–OCH3), 33.50 (C-900), 20.99 (–CH3); HRMS calcd




It was obtained as a white solid with a m.p. of 180.0–182.0 C in
68% yield. IR (KBr) nmax (cm
1) ¼ 2926 (C–H, Ar), 1684 (C]O),
1231 (C–O), 823 (C–S–C); 1H NMR (400MHz, CDCl3) d 7.98 (s, 1H,
H-5), 7.59 (d, J¼ 8.4 Hz, 2H, Ar), 7.40–7.36 (m, 2H, Ar), 7.31 (d, J¼
8.4 Hz, 2H, Ar), 7.24–7.20 (m, 2H, Ar), 7.03 (d, J¼ 8.8 Hz, 2H, Ar),
6.94 (d, J¼ 8.8 Hz, 2H, Ar), 6.04 (s, 1H, H-700), 5.23 (s, 2H, –OCH2),
3.95 (dd, J ¼ 1.2, 15.6 Hz, 1H, H-900), 3.85 (d, J ¼ 15.6 Hz, 1H,
H-900), 2.42 (s, 3H, –CH3);
13C NMR (100 MHz, CDCl3) d 170.87
(C-1000), 158.64 (C-100), 144.26, 139.10, 136.44, 134.55, 132.17,
131.26, 130.26, 128.57, 127.22, 120.97, 120.58, 120.46, 115.09,
64.98 (C-700), 61.95 (–OCH2), 33.47 (C-900), 21.07 (–CH3); HRMS
calcd for C25H21BrN4O2SH: 522.4368; found [M + H]
+: 522.4360.
3-(3-Fluorophenyl)-2-[4-{(1-(p-tolyl)-1H-1,2,3-triazol-4-yl)
methoxy}phenyl] thiazolidin-4-one(8r).This journal is © The Royal Society of Chemistry 2015It was obtained as a white solid with a m.p. of 276–278 C in
76% yield. IR (KBr) nmax (cm
1) ¼ 2928 (C–H, Ar), 1638 (C]O),
1255 (C–O), 825 (C–S–C); 1H NMR (400 MHz, CDCl3) d 8.05 (s,
1H, H-5), 7.41 (d, J ¼ 8.05 Hz, 2H, Ar), 7.54 (t, J ¼ 7.32 Hz, 2H,
Ar), 7.49–7.45 (m, 1H, Ar), 7.26 (d, J ¼ 8.05 Hz, 2H, Ar), 7.08 (d,
J ¼ 7.32 Hz, 2H, Ar), 7.01 (d, J ¼ 8.05 Hz, 2H, Ar), 6.94 (d, J ¼
8.05 Hz, 1H, Ar), 6.04 (s, 1H, H-700), 5.26 (s, 2H, –OCH2), 3.98
(d, J ¼ 16.11 Hz, 1H, H-900), 3.88 (d, J ¼ 16.11 Hz, 1H, H-900),
2.26 (s, 3H, –CH3);
13C NMR (100 MHz, CDCl3) d 170.04 (C-
1000), 157.66 (C-100), 143.11, 138.07, 133.64, 130.45, 129.37,
127.69, 120.84, 120.19, 119.47, 114.14, 112.86, 112.66, 112.19,
111.95, 63.74 (C-700), 60.75 (–OCH2), 32.56 (C-900), 20.17 (–CH3);





It was obtained as a yellowish solid with a m.p. of 170.0–172.0
C in 76% yield. IR (KBr) nmax (cm
1) ¼ 2924 (C–H, Ar), 1683
(C]O), 1248 (C–O), 757 (C–S–C); 1H NMR (400 MHz, CDCl3) d
7.92 (s, 1H, H-5), 7.64–7.60 (m, 2H, Ar), 7.29–7.23 (m, 4H, Ar),
7.18–7.12 (m, 2H, Ar), 7.04–7.01 (m, 2H, Ar), 6.92 (d, J ¼ 8.05
Hz, 2H, Ar), 6.07 (s, 1H, H-700), 5.22 (s, 2H, –OCH2), 4.00–3.85
(m, 5H, H-900 & –OCH3);
13C NMR (100 MHz, CDCl3) d 170.93 (C-
1000), 159.88 (C-40), 158.49 (C-100), 144.23, 137.36, 131.75,
130.26, 129.04, 128.59, 127.09, 125.85, 122.20, 121.11, 114.93,
114.73, 65.28 (C-700), 61.91 (–OCH2), 55.58 (–OCH3), 33.52 (C-





It was obtained as a yellow solid with a m.p. of 131.0–133.0 C in
76% yield. IR (KBr) nmax (cm
1) ¼ 2925 (C–H, Ar), 1685 (C]O),
1230 (C–O), 837 (C–S–C); 1H NMR (300 MHz, CDCl3) d 7.93 (s,
1H, H-5), 7.86 (dd, J ¼ 2.8, 8.8 Hz, 2H, Ar), 7.60 (dd, J ¼ 2.8, 8.8
Hz, 2H, Ar), 7.32 (dd, J ¼ 2.8, 8.8 Hz, 2H, Ar), 7.26–7.22 (m, 2H,
Ar), 7.03–6.99 (m, 2H, Ar), 6.94–6.91 (m, 2H, Ar), 6.18 (s, 1H,
H-700), 5.21 (s, 2H, –OCH2), 3.99–3.83 (m, 5H, H-900 & –OCH3),
2.52 (s, 3H, –COCH3);
13C NMR (100 MHz, CDCl3) d 197.37
(–COCH3), 176.27 (C-1000), 171.16, 159.61 (C-40), 158.57 (C-100),
141.78, 134.72, 131.13, 129.14, 128.35, 124.68, 122.24, 115.15,
114.80, 64.70 (C-700), 61.80 (–OCH2), 55.61 (–OCH3), 33.60 (C-900),RSC Adv., 2015, 5, 1628–1639 | 1635
RSC Advances Paper26.50 (–COCH3); HRMS calcd for C27H24N4O4SH: 501.5768;
found [M + H]+: 501.5760.
3-(3-Acetylphenyl)-2-[4-{(1-(4-methoxyphenyl)-1H-1,2,3-
triazol-4-yl)methoxy}phenyl] thiazolidin-4-one (8u).
It was obtained as a brown semi solid in 83% yield. IR (KBr)
nmax (cm
1) ¼ 2922 (C–H, Ar), 1683 (C]O), 1247 (C–O), 759
(C–S–C); 1H NMR (300 MHz, CDCl3) d 7.93 (s, 1H, H-5), 7.74–
7.71 (m, 2H, Ar), 7.62–7.58 (m, 2H, Ar), 7.38–7.36 (m, 1H, Ar),
7.27–7.24 (m, 2H, Ar), 7.02–6.99 (m, 2H, Ar), 6.93–6.90 (m, 2H,
Ar), 6.11 (s, 1H, H-700), 5.20 (s, 2H, –OCH2), 4.01–3.86 (m, 5H,
H-900 & –OCH3), 2.50 (s, 3H, –COCH3);
13C NMR (100 MHz,
CDCl3) d 197.12 (–COCH3), 171.17 (C-1000), 159.94 (C-40),
159.60 (C-100), 144.09, 131.08, 130.48, 130.15, 129.31, 128.72,
126.91, 125.25, 122.21, 121.22, 115.04, 114.75, 65.08 (C-700),
61.79 (–OCH2), 55.59 (–OCH3), 33.54 (C-900), 26.55 (–COCH3);





It was obtained as a white solid with a m.p. of 100–102 C in
79% yield. IR (KBr) nmax (cm
1) ¼ 2923 (C–H, Ar), 1683 (C]O),
1238 (C–O), 758 (C–S–C); 1H NMR (300 MHz, CDCl3) d 7.93 (s,
1H, H-5), 7.61 (dd, J ¼ 2.8, 8.8 Hz, 2H, Ar), 7.26–7.22 (m, 2H,
Ar), 7.07–6.97 (m, 6H, Ar), 6.92 (dd, J¼ 2.8, 8.8 Hz, 2H, Ar), 6.02
(s, 1H, H-700), 5.21 (s, 2H, –OCH2), 3.99–3.83 (m, 5H, H-900 &
–OCH3), 2.24 (s, 3H, –CH3);
13C NMR (100 MHz, CDCl3) d
171.10 (C-1000), 159.98 (C-40), 158.45 (C-100), 144.18, 137.18,
134.45, 131.92, 129.76, 128.69, 125.90, 122.25, 121.22, 114.91,
114.78, 65.44 (C-700), 61.82 (–OCH2), 55.61 (–OCH3), 33.50 (C-
900), 20.99 (–CH3); HRMS calcd for C26H24N4O3SH: 473.5667;
found [M + H]+: 473.5662.
2-[4-{(1-(4-Methoxyphenyl)-1H-1,2,3-triazol-4-yl)methoxy}
phenyl]-3-(m-tolyl) thiazolidin-4-one (8w).
It was obtained as a white solid with a m.p. of 158.0–160.0 C in1636 | RSC Adv., 2015, 5, 1628–163973% yield. IR (KBr) nmax (cm
1) ¼ 2925 (C–H, Ar), 1677 (C]O),
1241 (C–O), 833 (C–S–C); 1H NMR (300 MHz, CDCl3) d 7.93 (s,
1H, H-5), 7.60 (dd, J¼ 3.2, 8.8 Hz, 2H, Ar), 7.26–7.22 (m, 2H, Ar),
7.16–7.10 (m, 1H, Ar), 7.02–6.86 (m, 7H, Ar), 6.04 (s, 1H, H-700),
5.21 (s, 2H, –OCH2), 3.99–3.82 (m, 5H, H-900 & –OCH3), 2.25 (s,
3H, –CH3);
13C NMR (100 MHz, CDCl3) d 173.56 (C-1000), 171.09,
159.92 (C-40), 158.40 (C-100), 144.15, 138.98, 137.13, 131.83,
130.13, 128.78, 128.59, 128.07, 126.65, 122.93, 122.18, 121.20,
114.88, 114.72, 65.39 (C-700), 61.79 (–OCH2), 55.56 (–OCH3),
33.49 (C-900), 21.25 (–CH3); HRMS calcd for C26H24N4O3SH:
473.5667; found [M + H]+: 473.5665.
3-(4-Methoxyphenyl)-2-[4-{(1-(4-methoxyphenyl)-1H-1,2,3-
triazol-4-yl)methoxy}phenyl] thiazolidin-4-one (8x).
It was obtained as a white solid with a m.p. of 164.0–166.0 C
in 87% yield. IR (KBr) nmax (cm
1) ¼ 2923 (C–H, Ar), 1681
(C]O), 1248 (C–O), 759 (C–S–C); 1H NMR (300 MHz, CDCl3) d
7.93 (s, 1H, H-5), 7.61 (d, J ¼ 8.8 Hz, 2H, Ar), 7.24 (d, J ¼ 8.8
Hz, 2H, Ar), 7.02–6.96 (m, 4H, Ar), 6.92 (d, J ¼ 8.4 Hz, 2H, Ar),
6.77 (d, J ¼ 8.8 Hz, 2H, Ar), 5.95 (s, 1H, H-700), 5.22 (s, 2H,
–OCH2), 3.98–3.84 (m, 5H, H-900 & –OCH3), 3.71 (s, 3H,
–OCH3);
13C NMR (100 MHz, CDCl3) d 171.00 (C-1000), 159.98,
158.41 (C-100), 144.17, 131.95, 130.17, 129.94, 128.81, 127.60,
122.25, 121.28, 114.91, 114.78, 114.40, 65.58 (C-700), 61.89
(–OCH2), 55.60 (–OCH3), 55.28 (–OCH3), 33.39 (C-900);





It was obtained as a yellow solid with a m.p. of 156.0–158.0 C in
80% yield. IR (KBr) nmax (cm
1) ¼ 2929 (C–H, Ar), 1682 (C]O),
1255 (C–O), 753 (C–S–C); 1H NMR (300 MHz, CDCl3) d 7.91
(s, 1H, H-5), 7.61 (dd, J ¼ 3.2, 8.8 Hz, 2H, Ar), 7.28–7.25 (m, 2H,
Ar), 7.20–7.14 (m, 1H, Ar), 7.03–6.99 (m, 2H, Ar), 6.90–6.78 (m,
5H, Ar), 6.06 (s, 1H, H-700), 5.21 (s, 2H, –OCH2), 3.91–3.82 (m, 8H,
H-900, 2 –OCH3); 13C NMR (100 MHz, CDCl3) d 171.32 (C-1000),
159.86 (C-40), 158.48 (C-1200), 154.76 (C-100), 144.22, 131.34,
130.32, 130.23, 129.44, 129.35, 125.32, 122.17, 121.10, 120.70,
114.71, 114.51, 111.80, 64.27 (C-700), 61.84 (–OCH2), 55.58
(–OCH3), 33.22 (C-900); HRMS calcd for C26H24N4O4SH: 489.5661;
found [M + H]+: 489.5665.This journal is © The Royal Society of Chemistry 2015
Paper RSC Advances3-(4-Bromophenyl)-2-[4-{(1-(4-methoxyphenyl)-1H-1,2,3-
triazol-4-yl)methoxy}phenyl] thiazolidin-4-one (8z).
It was obtained as a yellow solid with a m.p. of 104.0–106.0 C in
74% yield. IR (KBr) nmax (cm
1) ¼ 2957 (C–H, Ar), 1637 (C]O),
1249 (C–O), 756 (C–S–C); 1H NMR (400 MHz, CDCl3) d 7.95
(s, 1H, H-5), 7.59 (d, J¼ 8.79 Hz, 2H, Ar), 7.36 (d, J¼ 8.79 Hz, 2H,
Ar), 7.20 (d, J ¼ 9.15 Hz, 2H, Ar), 7.00 (d, J ¼ 8.79 Hz, 4H, Ar),
6.91 (d, J ¼ 8.05 Hz, 2H, Ar), 6.02 (s, 1H, H-700), 5.23 (s, 2H,
–OCH2), 3.95–3.82 (m, 5H, H-900 & –OCH3);
13C NMR (100 MHz,
CDCl3) d 171.11 (C-1000), 160.05 (C-40), 158.59 (C-100), 136.67,
132.19, 131.33, 130.17, 128.61, 127.24, 122.27, 121.26, 120.60,
115.10, 114.83, 65.00 (C-700), 61.82 (OCH2), 55.64 (–OCH3), 33.49




It was obtained as a yellowish solid with a m.p. of 167.0–169.0
C in 75% yield. IR (KBr) nmax (cm
1) ¼ 2922 (C–H, Ar), 1689
(C]O), 1255 (C–O), 756 (C–S–C); 1H NMR (300 MHz, CDCl3) d
7.92 (s, 1H, H-5), 6.97 (d, J ¼ 8.8 Hz, 2H, Ar), 6.62–6.52 (m, 3H,
Ar), 6.39–6.28 (m, 6H, Ar), 6.24–6.19 (m, 1H, Ar), 5.43 (s, 1H, H-
700), 4.59 (s, 2H, –OCH2), 3.33–3.19 (m, 5H, H-900 & –OCH3);
13C
NMR (100 MHz, CDCl3) d 170.95 (C-1000), 160.02 (C-40), 158.56
(C-100), 144.09, 139.04, 131.44, 130.21, 128.43, 122.30, 115.15,
114.81, 114.06, 113.09, 65.01 (C-700), 62.02 (–OCH2), 55.63
(–OCH3), 33.49 (C-900); HRMS calcd for C25H21FN4O3SH:
477.5306; found [M + H]+: 477.5300.
3-(4-Fluorophenyl)-2-[4-{(1-(4-methoxyphenyl)-1H-1,2,3-
triazol-4-yl)methoxy}phenyl] thiazolidin-4-one (8b0).
It was obtained as a brown solid with a m.p. of 76.0–78.0 C in
78% yield. IR (KBr) nmax (cm
1) ¼ 2925 (C–H, Ar), 1682 (C]O),
1237 (C–O), 757 (C–S–C); 1H NMR (300 MHz, CDCl3) d 7.93
(s, 1H, H-5), 7.61 (dd, J ¼ 2.4, 8.8 Hz, 2H, Ar), 7.24–7.21 (m, 1H,This journal is © The Royal Society of Chemistry 2015Ar), 7.10–6.92 (m, 8H, Ar), 6.00 (s, 1H, H-700), 5.23 (s, 2H, –OCH2),
3.99–3.84 (m, 5H, H-900 & –OCH3);
13C NMR (100 MHz, CDCl3) d
170.01 (C-1000), 160.03 (C-40), 158.47 (C-100), 144.23, 131.42,
128.86, 128.03, 122.24, 121.13, 116.20, 115.98, 115.04, 114.79,
65.38 (C-700), 61.89 (–OCH2), 55.68 (–OCH3), 33.42; HRMS calcd




It was obtained as a yellowish solidwith am.p. of. 84.0–86.0 C in
85% yield. IR (KBr) nmax (cm
1) ¼ 2923 (C–H, Ar), 1688 (C]O),
1249 (C–O), 757 (C–S–C); 1HNMR (400MHz, CDCl3) d 7.98 (s, 1H,
H-5), 7.61 (d, J ¼ 8.79 Hz, 2H, Ar), 7.26–7.21 (m, 4H, Ar), 7.07 (d,
J¼ 8.79 Hz, 2H, Ar), 7.02 (d, J¼ 8.79 Hz, 2H, Ar), 6.93 (d, J¼ 8.05
Hz, 2H, Ar), 6.03 (s, 1H, H-700), 5.25 (s, 2H, –OCH2), 3.97–3.84 (m,
5H, H-900 & –OCH3),;
13C NMR (100MHz, CDCl3) d 171.01 (C-1000),
160.13 (C-40), 158.59 (C-100), 135.92, 132.65, 132.04, 131.37,
129.24, 128.63, 126.99, 122.28, 115.10, 114.85, 65.09 (C-700), 61.83
(–OCH2), 55.63 (–OCH3), 33.47 (C-900); HRMS calcd for C25H21-




It was obtained as a light brown solid with a m.p. of 103.0–105.0
C in 77% yield. IR (KBr) nmax (cm
1) ¼ 2930 (C–H, Ar), 1702
(C]O), 1256 (C–O), 830 (C–S–C); 1H NMR (300 MHz, CDCl3) d
7.93 (s, 1H, H-5), 7.61 (d, J ¼ 8.79 Hz, 2H, Ar), 7.42–7.38 (m, 1H,
Ar), 7.32–7.29 (m, 2H, Ar), 7.23–7.07 (m, 3H, Ar), 7.03–7.00 (m,
2H, Ar), 6.93–6.90 (m, 2H, Ar), 6.04 (s, 1H, H-700), 5.23 (s, 2H,
–OCH2), 3.94–3.81 (m, 5H, H-900 & –OCH3);
13C NMR (100 MHz,
CDCl3) d 176.47 (C-1000), 159.98 (C-40), 158.33 (C-100), 144.37,
130.69, 130.28, 129.52, 122.28, 121.24, 115.00, 114.80, 62.14
(C-700), 55.63 (–OCH2), 51.54 (–OCH3), 33.42 (C-900); HRMS
calcd for C25H21ClN4O3SH: 493.1101; found [M + H]
+: 493.1112.Acknowledgements
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